142 related articles for article (PubMed ID: 19559112)
1. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Wedemeyer H; Schuller E; Schlaphoff V; Stauber RE; Wiegand J; Schiefke I; Firbas C; Jilma B; Thursz M; Zeuzem S; Hofmann WP; Hinrichsen H; Tauber E; Manns MP; Klade CS
Vaccine; 2009 Aug; 27(37):5142-51. PubMed ID: 19559112
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
Klade CS; Wedemeyer H; Berg T; Hinrichsen H; Cholewinska G; Zeuzem S; Blum H; Buschle M; Jelovcan S; Buerger V; Tauber E; Frisch J; Manns MP
Gastroenterology; 2008 May; 134(5):1385-95. PubMed ID: 18471515
[TBL] [Abstract][Full Text] [Related]
3. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
Schlaphoff V; Klade CS; Jilma B; Jelovcan SB; Cornberg M; Tauber E; Manns MP; Wedemeyer H;
Vaccine; 2007 Sep; 25(37-38):6793-806. PubMed ID: 17686555
[TBL] [Abstract][Full Text] [Related]
4. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.
Barnes E; Harcourt G; Brown D; Lucas M; Phillips R; Dusheiko G; Klenerman P
Hepatology; 2002 Sep; 36(3):743-54. PubMed ID: 12198669
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
Yutani S; Yamada A; Yoshida K; Takao Y; Tamura M; Komatsu N; Ide T; Tanaka M; Sata M; Itoh K
Vaccine; 2007 Oct; 25(42):7429-35. PubMed ID: 17845828
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.
Firbas C; Boehm T; Buerger V; Schuller E; Sabarth N; Jilma B; Klade CS
Vaccine; 2010 Mar; 28(12):2397-407. PubMed ID: 20060945
[TBL] [Abstract][Full Text] [Related]
7. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
[TBL] [Abstract][Full Text] [Related]
8. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection.
Jeong HY; Lee YJ; Seo SK; Lee SW; Park SJ; Lee JN; Sohn HS; Yao S; Chen L; Choi I
J Leukoc Biol; 2008 Mar; 83(3):755-64. PubMed ID: 18086898
[TBL] [Abstract][Full Text] [Related]
9. [Chronic hepatitis C infection--mechanisms of virus "immune escape"].
Nitkiewicz J
Przegl Epidemiol; 2004; 58(3):423-33. PubMed ID: 15730006
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C in the advanced adult and elderly subjects.
Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infection.
van den Berg CH; Ruys TA; Nanlohy NM; Geerlings SE; van der Meer JT; Mulder JW; Lange JA; van Baarle D
J Viral Hepat; 2009 Apr; 16(4):239-48. PubMed ID: 19222746
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
Firbas C; Jilma B; Tauber E; Buerger V; Jelovcan S; Lingnau K; Buschle M; Frisch J; Klade CS
Vaccine; 2006 May; 24(20):4343-53. PubMed ID: 16581161
[TBL] [Abstract][Full Text] [Related]
13. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C.
Heeg MH; Ulsenheimer A; Grüner NH; Zachoval R; Jung MC; Gerlach JT; Raziorrouh B; Schraut W; Horster S; Kauke T; Spannagl M; Diepolder HM
Gastroenterology; 2009 Oct; 137(4):1280-8.e1-6. PubMed ID: 19596013
[TBL] [Abstract][Full Text] [Related]
14. The effect of controlled therapy interruption in chronic HCV infection: enhanced host immune response? A hypothesis.
Lake-Bakaar G
J Clin Virol; 2009 Feb; 44(2):149-51. PubMed ID: 19157972
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
Mariano A; Caserta C; Pendino GM; Vacalebre C; Surace P; Fiorillo MT; Polito I; Surace M; Alicante S; Amante A; Foti G; Marra M; Gutamo G; Amato F; Messineo A; Mele A
Dig Liver Dis; 2009 Jul; 41(7):509-15. PubMed ID: 19196557
[TBL] [Abstract][Full Text] [Related]
16. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection.
Denholm JT; Wright EJ; Street A; Sasadeusz JJ
Haemophilia; 2009 Mar; 15(2):538-43. PubMed ID: 19187189
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
[TBL] [Abstract][Full Text] [Related]
18. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.
Rehermann B
Semin Liver Dis; 2007 May; 27(2):152-60. PubMed ID: 17520515
[TBL] [Abstract][Full Text] [Related]
19. In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells.
Krishnadas DK; Li W; Kumar R; Tyrrell LJ; Agrawal B
Cell Immunol; 2009; 259(2):141-9. PubMed ID: 19616202
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of interferon in hepatitis B and C.
Schalm SW
Verh K Acad Geneeskd Belg; 2009; 71(1-2):87-99. PubMed ID: 19739400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
